Mycophenolate Mofetil Powder, For Suspension
Product Images NDC 72603-751
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Mycophenolate Mofetil (NDC 72603-751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Fig2 (Mycophenolate Fig2)
Package Label-principal Display Panel 200 mg/ml (225 mL Bottle) (Mycophenolate Fig3)
This text is a description of Mycophenolate Mofetil oral suspension, which contains 200 mg/mL of the active ingredient. It provides instructions for pharmacists on how to prepare the suspension and states dosage information. Storage recommendations are also included, with details on permissible temperature excursions. It mentions the expiry date, proper shaking before use, and the need to discard any unused portion after 60 days. Additionally, it provides contact information for medication guides and manufacturer details.*
Package Label-principal Display Panel (200 mg/mL (225 mL Carton Label))
This is a description of Mycophenolate Mofetil for Oral Suspension, USP at a concentration of 200 mg/mL. The text provides detailed instructions for pharmacists on dispensing and constitution, mentioning the need to dispense a Medication Guide to each patient. It also includes dosage recommendations and storage information. The medication is manufactured by APL Healthcare Limited, India, and distributed by Northstar Rx LLC. For more information, visit www.northstarrxllc.com or call 1-800-206-7821.*
Str (Mycophenolate Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.